ATXN7L1

Across TCGA pan-cancer cohorts, ATXN7L1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ATXN7L1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATXN7L1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATXN7L1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM and LUAD are the cancer types where ATXN7L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.860	0.254	.004	14	view →
LUAD	OS	Median	All	0.929	0.380	.004	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ATXN7L1–GBM (OS)

Open the GBM breakdown →